Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Prospective, Multicenter Clinical Trial of Everolimus As Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

Steven P Treon, MD PhD, Kirsten Meid, MPH, Christina K. Tripsas, MA, Leonard T. Heffner, MD, Herbert Eradat, Ashraf Z Badros, MD, Lian Xu, Zachary Hunter, PhD, Guang Yang, PhD, Christopher J Patterson, MFA, Joshua Gustine, MPH, Jorge J. Castillo, MD, Jeffrey V. Matous, MD, Irene M. Ghobrial, MD

Blood (2016) 128 (22): 4487.

https://doi.org/10.1182/blood.V128.22.4487.4487

Published: 2016

Journal Articles

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Steven P. Treon, Christina K. Tripsas, Kirsten Meid, Sandra Kanan, Patricia Sheehy, Stacey Chuma, Lian Xu, Yang Cao, Guang Yang, Xia Liu, Christopher J. Patterson, Diane Warren, Zachary R. Hunter, Barry Turnbull, Irene M. Ghobrial, Jorge J. Castillo

Blood (2014) 124 (4): 503–510.

https://doi.org/10.1182/blood-2014-03-566273

Published: 2014

Journal Articles

Highly Recurrent Copy Number Alterations and Insight Into The Origins Of 6q Deletions In Waldenström’s Macroglobulinemia Revealed By Whole Genome Sequencing

Zachary Hunter, Lian Xu, Guang Yang, PhD, Xia Liu, MD, Yang Cao, MD, Robert Manning, Christina K Tripsas, MA, Christopher Patterson, Steven Peter Treon, MD, MA, PhD

Blood (2013) 122 (21): 4254.

https://doi.org/10.1182/blood.V122.21.4254.4254

Published: 2013

Journal Articles

Somatic Activating Mutations In CXCR4 Are Common In Patients With Waldenstrom’s Macroglobulinemia, and Their Expression In WM Cells Promotes Resistance To Ibrutinib

Yang Cao, MD, Zachary Hunter, Xia Liu, MD, Lian Xu, Guang Yang, PhD, Christina K Tripsas, MA, Robert Manning, Christopher Patterson, Steven Peter Treon, MD, MA, PhD

Blood (2013) 122 (21): 4424.

https://doi.org/10.1182/blood.V122.21.4424.4424

Published: 2013

Journal Articles

Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Kirsten Meid, MPH, Christopher Patterson, Leonard T Heffner, MD, Herbert Eradat, MS, MD, Stephanie A. Gregory, MD, Sheeba K. Thomas, M.D., Ranjana H. Advani, MD, Rachid Baz, Ashraf Z. Badros, MD, Jeffrey Matous, MD, Timothy J. Murphy, MD, FACP, Irene M. Ghobrial, MD

Blood (2013) 122 (21): 1822.

https://doi.org/10.1182/blood.V122.21.1822.1822

Published: 2013

Journal Articles

Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance

Lian Xu, Zachary Hunter, Guang Yang, PhD, Yangsheng Zhou, MD, Xia Liu, MD, Yang Cao, MD, Robert Manning, Christopher Patterson, Christina K Tripsas, MA, Sandra Kanan, NP, Jiaji G Chen, Neil I Lindeman, MD, Steven Peter Treon, MD, MA, PhD

Blood (2013) 122 (21): 3024.

https://doi.org/10.1182/blood.V122.21.3024.3024

Published: 2013

Journal Articles

PI3K/AKT Pathway Is Activated By MYD88 L265P and Use Of PI3K-Delta Inhibitors Induces Robust Tumor Cell Killing In Waldenstrom’s Macroglobulinemia

Guang Yang, PhD, Xia Liu, MD, Yangsheng Zhou, MD, Lian Xu, Yang Cao, MD, Robert Manning, Christopher Patterson, Christina K Tripsas, MA, Zachary Hunter, Sara Buhrlage, Ph.D, Nathanael S Gray, PhD, Steven Peter Treon, MD, MA, PhD

Blood (2013) 122 (21): 4255.

https://doi.org/10.1182/blood.V122.21.4255.4255

Published: 2013

Journal Articles

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Kirsten Meid, MPH, Steven J Cropper, Patrick Mostyn, Diane Warren, Claudia E. Paba-Prada, MD, Christopher Patterson, Guang Yang, PhD, Zachary Hunter, Janet Kunsman, NP, Sandra Kanan, NP, Irene M. Ghobrial, MD

Blood (2013) 122 (21): 757.

https://doi.org/10.1182/blood.V122.21.757.757

Published: 2013

Journal Articles

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Guang Yang, PhD, Yang Cao, MD, Lian Xu, Zachary Hunter, Steven J Cropper, Patrick Mostyn, Kirsten Meid, MPH, Diane Warren, Christopher Patterson, Gaurav Varma, MSPH, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Janet Kunsman, NP, Irene M. Ghobrial, MD, Sandra Kanan, NP, Ranjana H. Advani, MD, Maria Lia Palomba, MD

Blood (2013) 122 (21): 251.

https://doi.org/10.1182/blood.V122.21.251.251

Published: 2013

Journal Articles

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

Blood (2013) 121 (11): 2051–2058.

https://doi.org/10.1182/blood-2012-09-454355

Published: 2013

Journal Articles

Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia

Steven P Treon, MD, PhD, Christina K Tripsas, Leukothea Ioakimidis, Diane Warren, Christopher Patterson, Leonard Heffner, MD, Herbert Eradat, MD, MS, Stephanie A. Gregory, MD, Sheeba Thomas, MD, Ranjana Advani, MD, Rachid Baz, Ashraf Z. Badros, MD, Jeffrey Matous, MD, Kenneth C. Anderson, MD, Irene M. Ghobrial, MD

Blood (2011) 118 (21): 2951.

https://doi.org/10.1182/blood.V118.21.2951.2951

Published: 2011

NARROW

Prospective, Multicenter Clinical Trial of Everolimus As Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Highly Recurrent Copy Number Alterations and Insight Into The Origins Of 6q Deletions In Waldenström’s Macroglobulinemia Revealed By Whole Genome Sequencing

Somatic Activating Mutations In CXCR4 Are Common In Patients With Waldenstrom’s Macroglobulinemia, and Their Expression In WM Cells Promotes Resistance To Ibrutinib

Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstrom’s Macroglobulinemia

Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance

PI3K/AKT Pathway Is Activated By MYD88 L265P and Use Of PI3K-Delta Inhibitors Induces Robust Tumor Cell Killing In Waldenstrom’s Macroglobulinemia

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only